Von Willebrand Factor in Pregnancy Study: This study focuses on pregnant women with von Willebrand disease (VWD), a condition where the blood doesn’t clot properly due to low levels of von Willebrand factor (VWF) or Factor VIII (FVIII). By the third trimester of pregnancy, if these levels are low, it can cause issues during delivery. The study uses a treatment called Wilate to help increase VWF levels and reduce bleeding risks. The main goal is to see how well this treatment works and ensure it's safe.
Women in the study are divided into two groups: "non-correctors," who need the Wilate treatment, and "correctors," whose VWF levels naturally improve. All women will take tranexamic acid, a medicine that helps prevent bleeding, for 14 days after delivery. The study will measure bleeding rates after delivery and monitor safety.
- Time Commitment: The study involves monitoring until 65 non-correctors and up to 30 correctors complete the protocol.
- Treatment: Non-correctors receive Wilate therapy; all participants take tranexamic acid post-delivery.
- Eligibility: Women with VWD aged 18+; must not have other blood clotting disorders.
How understandable was the trial content above?
Hard to understand
Easy to understand